Bisphosphonates as a treatment modality in osteoarthritis.
Bisphosphonates
Bone marrow lesions
Osteoarthritis
Subchondral bone
Journal
Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
31
12
2019
revised:
15
03
2020
accepted:
31
03
2020
pubmed:
6
4
2020
medline:
22
6
2021
entrez:
6
4
2020
Statut:
ppublish
Résumé
Osteoarthritis (OA) is affecting large proportions of the population worldwide. So far, no effective disease modifying drug has been developed for this disease, limiting the therapeutic options to pain medications, physiotherapy and ultimately surgical approaches, mainly joint implant surgery. In vitro and animal studies have demonstrated that bisphosphonates have the potential to become effective modalities for the treatment of OA. This group of pharmacological agents modulates crucial aspects of OA pathogenesis (subchondral bone turnover and loss, bone marrow edema formation, cartilage degeneration and synovitis), and have shown clear efficacy in animal models of OA. Human studies have, however, so far been disappointing with only one of six clinical studies showing clear short-term efficacy. Possible reasons for these discrepancies will be discussed.
Identifiants
pubmed: 32247817
pii: S8756-3282(20)30132-0
doi: 10.1016/j.bone.2020.115352
pii:
doi:
Substances chimiques
Diphosphonates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115352Informations de copyright
Copyright © 2020. Published by Elsevier Inc.